Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
pionERA breast cancer study
PACTR202312893558608Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in breast cancer comparing Giredestrant plus CDK4/6 inhibitor with Fulvestrant plus CDK4/6 inhibitor (2 arms). Primary endpoints: Progression-Free Survival in the ESR1 mutation subgroup and Progression-Free Survival in the full analysis set population. Started Jan 2024; status: recruiting.
02
Drugs
giredestrantfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on PACTR202312893558608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202312893558608.